Jennifer D Goldman-Levine1, Karen W Lee. 1. Department of Pharmacy Practice, School of Pharmacy-Boston, Massachusetts College of Pharmacy and Health Sciences, 179 Longwood Avenue, Boston, MA 02115-5804, USA. jgoldman-levine@bos.mcphs.edu
Abstract
OBJECTIVE: To review the pharmacology, pharmacokinetics, clinical trial data, adverse effects, and role in therapy of insulin detemir. DATA SOURCES: Articles and meeting abstracts were identified through searches of MEDLINE (1996-June 2004), EMBASE (1980-June 2004), and International Pharmaceutical Abstracts (1970-June 2004) databases, and unpublished information was provided by the manufacturer. STUDY SELECTION AND DATA EXTRACTION: All available studies relating to insulin detemir's pharmacology were selected. Only human studies were used for pharmacokinetic, drug interaction, efficacy, and safety data. DATA SYNTHESIS: Insulin detemir is a basal insulin analog that has been shown to improve glycemic control in patients with type 1 and type 2 diabetes. CONCLUSIONS: Insulin detemir offers some benefits over NPH for use as basal insulin in patients with type 1 and type 2 diabetes.
OBJECTIVE: To review the pharmacology, pharmacokinetics, clinical trial data, adverse effects, and role in therapy of insulin detemir. DATA SOURCES: Articles and meeting abstracts were identified through searches of MEDLINE (1996-June 2004), EMBASE (1980-June 2004), and International Pharmaceutical Abstracts (1970-June 2004) databases, and unpublished information was provided by the manufacturer. STUDY SELECTION AND DATA EXTRACTION: All available studies relating to insulin detemir's pharmacology were selected. Only human studies were used for pharmacokinetic, drug interaction, efficacy, and safety data. DATA SYNTHESIS: Insulin detemir is a basal insulin analog that has been shown to improve glycemic control in patients with type 1 and type 2 diabetes. CONCLUSIONS:Insulin detemir offers some benefits over NPH for use as basal insulin in patients with type 1 and type 2 diabetes.
Authors: Yunxiang Zhu; Ji-Lei Jiang; Nathan K Gumlaw; Jinhua Zhang; Scott D Bercury; Robin J Ziegler; Karen Lee; Mariko Kudo; William M Canfield; Timothy Edmunds; Canwen Jiang; Robert J Mattaliano; Seng H Cheng Journal: Mol Ther Date: 2009-03-10 Impact factor: 11.454
Authors: Vijay Pandyarajan; Nelson B Phillips; Nischay Rege; Michael C Lawrence; Jonathan Whittaker; Michael A Weiss Journal: J Biol Chem Date: 2016-04-26 Impact factor: 5.157
Authors: Balamurugan Dhayalan; Yen-Shan Chen; Nelson B Phillips; Mamuni Swain; Nischay K Rege; Ali Mirsalehi; Mark Jarosinski; Faramarz Ismail-Beigi; Norman Metanis; Michael A Weiss Journal: Chemistry Date: 2020-03-18 Impact factor: 5.236
Authors: Arto Y Strandberg; Fabian J Hoti; Timo E Strandberg; Solomon Christopher; Jari Haukka; Pasi Korhonen Journal: PLoS One Date: 2016-03-31 Impact factor: 3.240
Authors: Elisabeth R Mathiesen; Norsiah Ali; Amra C Alibegovic; Eleni Anastasiou; Katarzyna Cypryk; Harold de Valk; Jorge Dores; Fidelma Dunne; Mari-Anne Gall; Santiago Duran Garcia; Hélène P Hanaire; Lise Lotte N Husemoen; Marina Ivanišević; Hans-Peter Kempe; David R McCance; Peter Damm Journal: Diabetes Care Date: 2021-07-30 Impact factor: 19.112